Heron Therapeutics (NASDAQ:HRTX) Announces Quarterly Earnings Results

Heron Therapeutics (NASDAQ:HRTXGet Rating) released its earnings results on Monday. The biotechnology company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.18), MarketWatch Earnings reports. The firm had revenue of $23.46 million during the quarter, compared to the consensus estimate of $22.61 million. Heron Therapeutics had a negative net margin of 255.58% and a negative return on equity of 159.70%. The company’s revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.58) EPS.

NASDAQ:HRTX opened at $3.61 on Tuesday. The stock has a fifty day moving average price of $5.35 and a 200-day moving average price of $7.92. The company has a market cap of $368.73 million, a price-to-earnings ratio of -1.60 and a beta of 1.37. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.90 and a current ratio of 3.58. Heron Therapeutics has a fifty-two week low of $3.60 and a fifty-two week high of $18.80.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Zullo Investment Group Inc. acquired a new stake in shares of Heron Therapeutics during the 4th quarter worth $30,000. LPL Financial LLC grew its holdings in shares of Heron Therapeutics by 8.7% during the 4th quarter. LPL Financial LLC now owns 16,250 shares of the biotechnology company’s stock worth $148,000 after purchasing an additional 1,307 shares in the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of Heron Therapeutics by 387.2% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 16,784 shares of the biotechnology company’s stock worth $179,000 after purchasing an additional 13,339 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Heron Therapeutics during the 4th quarter worth $167,000. Finally, Royal Bank of Canada grew its holdings in shares of Heron Therapeutics by 19.2% during the 3rd quarter. Royal Bank of Canada now owns 27,117 shares of the biotechnology company’s stock worth $290,000 after purchasing an additional 4,370 shares in the last quarter.

Several equities research analysts have commented on HRTX shares. Zacks Investment Research cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, February 9th. StockNews.com began coverage on Heron Therapeutics in a report on Thursday, March 31st. They set a “sell” rating on the stock. Cantor Fitzgerald decreased their target price on Heron Therapeutics from $20.00 to $12.00 in a report on Tuesday. Cowen decreased their price objective on Heron Therapeutics from $13.00 to $7.50 in a report on Tuesday. Finally, Needham & Company LLC decreased their price objective on Heron Therapeutics from $24.00 to $16.00 in a report on Tuesday, March 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Heron Therapeutics currently has a consensus rating of “Hold” and an average target price of $16.21.

Heron Therapeutics Company Profile (Get Rating)

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Articles

Earnings History for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.